Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report

被引：32

作者：

Lucchini, Matteo ^{[1
,2
]}

Bianco, Assunta ^{[1
,2
]}

Del Giacomo, Paola ^{[1
]}

De Fino, Chiara ^{[1
]}

Nociti, Viviana ^{[1
,2
]}

Mirabella, Massimiliano ^{[1
,2
]}

机构：

[1] Univ Cattolica Sacro Cuore, Fdn Policlin Univ A Gemelli IRCCS, Largo Agostino Gemelli 8, I-00168 Rome, Italy

[2] Univ Cattolica Sacro Cuore, Rome, Italy

来源：

MULTIPLE SCLEROSIS AND RELATED DISORDERS | 2020年 / 44卷

关键词：

COVID-19; Ocrelizumab; IgG; IgA; Serology; IGA;

D O I：

10.1016/j.msard.2020.102323

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

The emergency represented by the COVID-19 pandemic represents a new challenge for clinicians who deal with autoimmune diseases because of patients undergoing immunosuppressive therapy. Few cases of Multiple Sclerosis (MS) patients receiving ocrelizumab who contracted COVID-19 with a benign course have recently been published. We present the case of a MS patient with mild COVID-19 who developed SARS-CoV-2 specific IgA without IgG ten weeks after infection. Patients on B-cell depleting drugs have a reduced antibody immune response to viral neoantigens. A relative sparing of mucosal-associated lymphoid tissues (MALT) could be responsible for IgA response in our patient.

引用

页数：2

共 13 条

[1] What policy makers need to know about COVID-19 protective immunity [J].

Altmann, Daniel M. ;

Douek, Daniel C. ;

Boyton, Rosemary J. .

LANCET, 2020, 395 (10236) :1527-1529

[2] Evaluation of the EUROIMMUN Anti-SARS-CoV-2 ELISA Assay for detection of IgA and IgG antibodies [J].

Beavis, Kathleen G. ;

Matushek, Scott M. ;

Abeleda, Ana Precy F. ;

Bethel, Cindy ;

Hunt, Carlissa ;

Gillen, Stephanie ;

Moran, Angelica ;

Tesic, Vera .

JOURNAL OF CLINICAL VIROLOGY, 2020, 129

[3] Inducing Mucosal IgA: A Challenge for Vaccine Adjuvants and Delivery Systems [J].

Boyaka, Prosper N. .

JOURNAL OF IMMUNOLOGY, 2017, 199 (01) :9-16

[4] Persistence of Autoreactive IgA-Secreting B Cells Despite Multiple Immunosuppressive Medications Including Rituximab [J].

He, Yong ;

Shimoda, Michiko ;

Ono, Yoko ;

Villalobos, Itzel Bustos ;

Mitra, Anupam ;

Konia, Thomas ;

Grando, Sergei A. ;

Zone, John J. ;

Maverakis, Emanual .

JAMA DERMATOLOGY, 2015, 151 (06) :646-650

[5] COVID-19 in persons with multiple sclerosis treated with ocrelizumab - A pharmacovigilance case series [J].

Hughes, Richard ;

Pedotti, Rosetta ;

Koendgen, Harold .

MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 42

[6]

Krüttgen A, 2020, J CLIN VIROL, V128

[7] Duration of serum neutralizing antibodies for SARS-CoV-2: Lessons from SARS-CoV infection [J].

Lin, Qingqing ;

Zhu, Li ;

Ni, Zuowei ;

Meng, Haitao ;

You, Liangshun .

JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2020, 53 (05) :821-822

[8]

Montesinos Isabel, 2020, J Clin Virol, V128, P104413, DOI 10.1016/j.jcv.2020.104413

[9] Initial Serological Response after Prime-boost Pneumococcal Vaccination in Rheumatoid Arthritis Patients: Results of a Randomized Controlled Trial [J].

Nguyen, Mai T. T. ;

Lindegaard, Hanne ;

Hendricks, Oliver ;

Jorgensen, Charlotte Svaerke ;

Kantso, Bjorn ;

Friis-Moller, Nina .

JOURNAL OF RHEUMATOLOGY, 2017, 44 (12) :1794-1803

[10] COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role? [J].

Novi, Giovanni ;

Mikulska, Malgorzata ;

Briano, Federica ;

Toscanini, Federica ;

Tazza, Francesco ;

Uccelli, Antonio ;

Inglese, Matilde .

MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 42

← 1 2 →